ISAAC OGUNSEYITAN: Open Payments
NPI 1851872816 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,108 in 108 payments from 11 companies in 2025. Trend: 2023 $921 · 2024 $1,093 · 2025 $2,108
Food & beverage: $1,998Education: $109
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $586 |
| Teva Pharmaceuticals USA, Inc. | 23 | $438 |
| E.R. Squibb & Sons, L.L.C. | 16 | $191 |
| Vanda Pharmaceuticals Inc. | 8 | $171 |
| Alkermes, Inc. | 8 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $142 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| Lundbeck LLC | 6 | $100 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| ABBVIE INC. | 4 | $72 |
Products named: INGREZZA, COBENFY, UZEDY, FANAPT, ARISTADA, CAPLYTA, AUSTEDO XR, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
